This activates TP53‐dependent transcription of SAT1, inducing ferroptosis and suppressing tumor growth in prostate cancer patient‐derived organoids (PDOs) and in vivo with minimal toxicity. The gene discussed is TP53; the disease is prostate carcinoma.